A Phase Ib/II Clinical Study of BBI608 in
Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103), NCT02279719
PURPOSE OF THIS CLINICAL RESEARCH TRIAL:
This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608 in combination with sorafenib, or BBI503 in combination with sorafenib. The study population is adult patients with advanced hepatocellular carcinoma who have not received systemic chemotherapy.
MORE DETAILS ON THIS TRIAL:
14148 / NCT02279719 / Open 7-7-2017
TRIAL AVAILABLE AT THESE LOCATIONS:
All RMCC Locations